Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia

Published:2019-03-15 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Steeghs Elisabeth M. P.,Boer Judith M.,Hoogkamer Alex Q.,Boeree Aurélie,de Haas Valerie,de Groot-Kruseman Hester A.,Horstmann Martin A.,Escherich Gabriele,Pieters Rob,den Boer Monique L.

Funder

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Stichting Kinderen Kankervrij

KWF Kankerbestrijding

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-41078-4.pdf

Reference48 articles.

1. Moorman, A. V. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood reviews 26, 123–135, https://doi.org/10.1016/j.blre.2012.01.001 (2012).

2. Pui, C. H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371, 1030–1043, https://doi.org/10.1016/S0140-6736(08)60457-2 (2008).

3. Pieters, R. et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 34, 2591–2601, https://doi.org/10.1200/JCO.2015.64.6364 (2016).

4. Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 10, 125–134, https://doi.org/10.1016/S1470-2045(08)70339-5 (2009).

5. Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. The New England journal of medicine 360, 470–480, https://doi.org/10.1056/NEJMoa0808253 (2009).

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IKZF1 in acute lymphoblastic leukemia: the rise before the fall?;Leukemia & Lymphoma;2024-08-29

2. Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening;Heliyon;2024-07

3. Acquired copy number amplification at the MYC enhancer in human B‐precursor acute lymphoblastic leukemia cell lines;Cancer Science;2024-06-26

4. Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer;International Journal of Molecular Sciences;2024-06-21

5. IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia;Frontiers in Oncology;2024-04-03